Methodology We performed targeted transcriptomics analysis of 50 genes using qPCR and estrogen metabolism analyses using LC-MS/MS. The model systems were high-grade serous ovarian cancer (HGSOC) cell lines OVSAHO, Kuramochi, COV362, and immortalized normal ovarian epithelial HIO-80 cells. The results in cell lines were compared with public transcriptome and proteome data for the HGSOC tissues.

Results In all model systems, HGSOC cell lines and tissues, high steroid sulfatase expression, and weak/undetected aromatase (CYP19A1) expression supported the formation of estrogens from the E1-S precursor. In ovarian cancer cells, the metabolism of E1-S to estradiol was the highest in OVSAHO, followed by Kuramochi and COV362 cells, and decreased with increasing chemoresistance. In addition, higher HSD17B14 and CYP1A2 expressions were observed in highly chemoresistant COV362 cells and platinum-resistant tissues compared to HIO-80 cells and platinum-sensitive tissues. The HGSOC cell models differed in HSD17B10, CYP1B1, and NQO1 expression. Proteomic data also showed different levels of HSD17B10, CYP1B1, NQO1, and SULT1E1 between the four HGSOC subtypes: differentiated, immunoreactive, proliferative, and mesenchymal.

Conclusion The results of our study suggest that in HGSOCs, the metabolism of E1-S precursor into estrogens decreases with increasing chemoresistance and that HGSOC subtypes form different levels of estrogens and their metabolites. The estrogen-biosynthesis-associated targets identified in our research present a base for further studies leading to potential personalized treatment development.

2022-RA-1505-ESGO OVARIAN CANCER RETROSPECTIVE EUROPEAN (O’CARE) OBSERVATIONAL STUDY: ANALYSIS OF FIRST-LINE (1L) OUTCOMES IN PATIENTS WITH OVARIAN CANCER (OC) STRATIFIED BY NUMBER OF RISK FACTORS FOR PROGRESSION

Jonathan Krell, Thumulurua K Madhuri, Daniella Shaw, John McGarne, Anjana Anand, Andreas Hartkopf, Ana Herrero, Cheng Yech, Maria Masvidal, Jean-David Fumet, Gunther Rogmann, Francesco Rappagliesi, Celine Gavroille, Whitney York, Jeanne M. Schiller, Barbara Mascaligna, Elena McDermott, Ina Kalliann, Lars Hanker, Imperial College London, London, UK; Royal Surrey NHS Foundation Trust, Guildford, UK; The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK; Royal Cornwall Hospitals NHS Trust, Cornwall, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK; Universitätstiefenklinik Tübingen, Tübingen, Germany; Hospital Universitario Miguel Servet, Zaragoza, Spain; Queen Alexandra Hospital, Portsmouth, UK; Hospital Universitari Sant Joan de Reus, Tarragona, Spain; Centre Georges François Leclerc, Dijon, France; Helios Klinik Krefeld, Germany; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; Instituto de Cancerologia de Lorraine (ICL) Nancy – Unicancer, Vandœuvre-lès-Nancy, France; GSK, Philadelphia, PA; GSK, Stevenage, UK; GSK, Research Triangle, NC; Arbeitsgemeinschaft Gynäkologische Onkologie (AGO), University Hospital Schleswig-Holstein, Campus Lübeck, Germany.

Abstract 2022-RA-1505-ESGO Table 1 Outcomes by risk factors

<table>
<thead>
<tr>
<th>Risk Factors</th>
<th>Moderate risk</th>
<th>High risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of RFs</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PFS (55% CI) months</td>
<td>31.3 (12.4–NR)</td>
<td>12.6 (10.0–14.8)</td>
</tr>
<tr>
<td>eOS (90% CI) months</td>
<td>41.9 (41.2–NR)</td>
<td>NR</td>
</tr>
</tbody>
</table>

Conclusion This real-world analysis of patients with OC from 5 European countries demonstrated that higher numbers of RFs were associated with shorter median PFS and OS. This analysis provides real-world data relating to 1L treatment outcomes for patients with OC; if validated in clinical trials, the number of RFs could be a stratification factor for future 1L OC trials.

2022-RA-1515-ESGO IMPACT OF SURGICAL STAGING ON SURVIVAL OF LOW GRADE ENDOMETRIOD OVARIAN CANCER APPARENTLY CONFINED TO THE OVARY

Nicolò Bizzarri, Majdi Imterat, Robert Fruscio, Anna Myriam Perrone, Rosanna Mancari, Alexander Traut, Andrea Rosati, Andreas du Bois, Debora Ferrari, Pietra De Iaco, Nicola Bizzarri, Majdi Imterat, Robert Fruscio, Anna Myriam Perrone, Rosanna Mancari, Alexander Traut, Andrea Rosati, Andreas du Bois, Debora Ferrari, Pietra De Iaco, Raffaella Ergasti, Beyhan Ataseven, Silvia Volontè, Marco Tesari, Maria Teresa Perri, Florian Heitz, Nicole Concin, Francesco Fanfani, Enrico Vizza, Giovanni Scambia, Philipp Harter, Anna Fagotti.

Abstract 2022-RA-1515-ESGO Table 1

<table>
<thead>
<tr>
<th>Risk Factors</th>
<th>Moderate risk</th>
<th>High risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of RFs</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>PFS (55% CI) months</td>
<td>31.3 (12.4–NR)</td>
<td>12.6 (10.0–14.8)</td>
</tr>
<tr>
<td>eOS (90% CI) months</td>
<td>41.9 (41.2–NR)</td>
<td>NR</td>
</tr>
</tbody>
</table>

Conclusion This real-world study assessed the real-world burden of disease, treatment patterns, and outcomes in patients with OC in 5 European countries (UK, France, Germany, Spain, and Italy). The analysis presented provides real-world data on the cumulative impact of risk factors (RFs) on disease progression and survival following 1L treatment.

Methodology O’CARE was a multicentre, noninterventional medical chart review study of patients aged ≥18 years diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer from 1 January 2014 to 31 December 2015. Patients were classified into moderate- or high-risk categories based on number of RFs for progression (Table). High-risk patients were further grouped by total number of RFs. Patients were followed from index date (date of diagnosis) until last activity or study end (maximum follow of 4 years). Kaplan-Meier methodology was used to estimate progression-free survival (PFS) and overall survival (OS).

Results The analysis included 412 patients: 7 (1.7%) had moderate risk of progression, whereas 405 (98.3%) had high risk of progression (table 1). For those with high risk, 84 (20.4%), 133 (32.3%), 139 (33.7%), and 49 (11.9%) had 1, 2, 3, and 4 RFs, respectively. Median PFS was 31.3 months for patients with 0 RFs and 12.6, 7.9, 5.9, and 3.6 months for patients with 1, 2, 3, or 4 RFs, respectively. Median OS was 41.9 months for patients with 0 RFs and not reached, 25.0, 18.0, and 7.4 months for patients with 1, 2, 3, or 4 RFs, respectively.
**Introduction/Background** To assess the disease-free survival (DFS) of patients with low-grade endometrioid ovarian cancer apparently confined to the ovary, according to surgical staging. Secondary endpoint was to evaluate the DFS according to adjuvant chemotherapy.

**Methodology** Multicenter, retrospective, observational cohort study. Patients with endometrioid ovarian carcinoma, surgical procedure performed between 05/1985–12/2019, stage pT1 N0/N1/Nx Grade 1–2 were included. Patients were stratified according to completeness of surgical staging (complete defined as peritoneal and retroperitoneal staging), lymphadenectomy (defined as removal of any lymph node (LN) versus no LN assessment), and receipt of adjuvant chemotherapy.

**Results** 298 patients were included in the study period. 166 (55.7%) patients underwent complete surgical staging, and 199 (66.8%) patients underwent LN assessment (of these, 166 -83.4% had unilateral/bilateral pelvic and para-aortic/caval lymphadenectomy). 11 (5.5%) patients of those undergoing LN assessment showed pathologic metastatic LNs (FIGO-stage IIIA1). 9/11 (81.8%) were diagnosed with grade 2 endometrioid ovarian cancer. 155 (52.0%) underwent adjuvant chemotherapy. Median follow up time was 45 months (95% CI: 37.5–52.5). 5-year DFS and overall survival of the entire cohort were 89.8% and 96.2%, respectively. Patients undergoing complete surgical staging had a trend toward a better 5-year DFS comparing to incomplete surgical staging (92.4% versus 86.5%, respectively; p=0.051). Performance of lymphadenectomy (sampling/systematic) was associated with better 5-year DFS compared to no lymphadenectomy (91.9% versus 85.6%, respectively; p=0.016) (figure 1). Adjuvant chemotherapy did not impact 5-year DFS (p=0.552). At univariate analysis the only significant variable affecting DFS was the performance of lymphadenectomy (HR: 0.388; 95% CI: 0.174–0.866; p=0.021).

**Conclusion** In a retrospective multicenter series of low-grade endometrioid ovarian cancers apparently confined to the ovary, lymphadenectomy appeared to be associated with improved DFS. Adjuvant chemotherapy did not impact DFS. Nevertheless, the present results derive from a retrospective uncontrolled study, in which the indication for or against lymphadenectomy/adjuvant chemotherapy was not prospectively defined, causing potential significant selection bias.

---

**Abstracts**

**2022-RA-1517-ESGO**

**WROCLAW COMPREHENSIVE CANCER CENTRE 100 MONTHS EXPERIENCE IN CYTOREDUCTIVE SURGERY AND HYPERThERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS+HIPEC) IN PATIENTS WITH PERITONEAL CARCINOMATOSIS – INDICATIONS AND COMPLICATIONS OF THE PROCEDURE**

1Krzysztof Szewczyk, 2Marcin Jedryka, 3Marek Bebenek. 1Department of Surgical Oncology, Wroclaw Comprehensive Cancer Center, Wroclaw, Poland; 2Gynecological Oncology, Wroclaw Comprehensive Cancer Centre, Wroclaw, Poland; 3Surgical Oncology, Wroclaw Comprehensive Cancer Centre, Wroclaw, Poland

10.1136/ijgc-2022-ESGO.734

**Introduction/Background** Selected patients with peritoneal dissemination of gastrointestinal (colorectal and gastric cancer), ovarian and primary peritoneal cancers benefit from cytoreductive surgery (CRS) combined with intraperitoneal chemotherapy in hyperthermia (HIPEC). In Poland, only a few oncology centers regularly perform CRS+HIPEC procedures, while the demand for them has been set at a minimum of 2000 per year (Nowotwory Journal of Oncology 2014; 64, 6: 518–524).

The aim of the study was the analysis of number, indications and complications of CRS+HIPEC procedures analysis performed in the 1st Oncological Surgery Department of Wroclaw Comprehensive Cancer Center (WCCC), Poland, during the first 100 months of the procedure.

**Methodology** Demographic, clinical, oncological and technical aspects database of all WCCC patients undergoing CRS+HIPEC procedures was created. Data statistical analysis was performed with Statistica version 12.5 (StatSoft).

**Results** In the period from 01.2014 to 04.2022, a total of 232 CRS+HIPEC procedures were performed at WCCC, 28 per year on average (range 20–37). The indications were mainly ovarian (40%) and colorectal (39%) cancers, followed by peritoneal pseudomyxoma (7%), peritoneal mesothelioma (6%), gastric (3%) and other cancers (5%). The scope of surgical cytoreduction (CRS) was wide: from single peritoneal nodules to extensive multi-organ radical (CC-0) or almost radical (residuals up to 2.5 mm – CC-1) resections. All HIPEC procedures were performed in closed technique. Clavien-Dindo grade III and IV complications occurred in 14% of patients. There were no perioperative deaths recorded.

**Conclusion** CRS+HIPEC procedures are rarely performed, however safe and promising therapeutic option for different patients with primary and secondary peritoneal cancers.